Psychiatric Pharmacogenetics
Parnassia Groep B.V. is involved in clinical research on pharmacogenetics in psychiatry, with interest in how genetic factors may inform individualised medication dosing for people receiving treatment for mood disorder and anxiety disorder.
- Major depressive disorder
- Bipolar disorder
- Panic disorder
- Social phobia
- Generalised anxiety disorder
Its research activity in this area reflects a focus on medication selection and dosing in routine psychiatric care, particularly where treatment response and tolerability vary across patients.
Depressive and Anxiety Disorders
The sponsor also funds research across a broader set of depressive disorders and anxiety disorders, including conditions associated with persistent low mood, fear, avoidance, and functional impairment in everyday life.
- Major depressive disorder
- Bipolar disorder
- Panic disorder
- Specific phobia
- Agoraphobia
This area of interest centers on clinically relevant psychiatric syndromes managed in specialist mental health services.
Psychotic Disorders
Parnassia Groep B.V. is active in research involving psychotic disorder, with attention to schizophrenia and schizoaffective disorder, where symptom burden and treatment needs can be complex and long term.
- Schizophrenia
- Schizoaffective disorder
These studies place the sponsor within specialist psychiatric care for severe mental illness.
Substance Use and Dual Diagnosis
The sponsor’s portfolio includes research on cocaine use disorder in the context of opioid dependence and methadone treatment, highlighting interest in patients with co-occurring substance use and psychiatric needs.
- Cocaine use disorder
- Opioid agonist treatment
- Methadone
This therapeutic domain links addiction medicine with ongoing mental health care in routine clinical settings.
